Hims & Hers Health, Inc.

HIMS · Healthcare

$28.44

Capitalizzazione: 6.64B USDRendimento da dividendo:
AdvanceÈ un buon momento per comprare Hims & Hers Health, Inc.? Chiedi a Copenvest AIOttieni un'analisi Advance con AI su timing, rischio e cosa fanno gli investitori tracciati.Chiedi a Copenvest AI

Caricamento grafico…

Notizie

Ultime notizie su questo titolo

GlobeNewswire Inc.4 set 2026, 19:38

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

Rosen Law Firm has filed a class action lawsuit on behalf of Hims & Hers Health, Inc. investors for the period between August 4, 2025 and July 29, 2026. The lawsuit alleges that Hims made materially false and misleading statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promised consultations, and undisclosed regulatory scrutiny and potential penalties. Investors who purchased securities during the class period may be eligible for compensation.

GlobeNewswire Inc.4 set 2026, 17:45

Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026

Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.

GlobeNewswire Inc.4 set 2026, 17:41

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) for allegedly making material misstatements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions immediately despite promising consultation with medical providers. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 can seek lead plaintiff status by November 2, 2026.

GlobeNewswire Inc.3 set 2026, 13:00

Deadline Approaching: Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.

GlobeNewswire Inc.2 set 2026, 21:34

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.